GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » Return-on-Tangible-Asset

Axonics (Axonics) Return-on-Tangible-Asset : -14.19% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Axonics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Axonics's annualized Net Income for the quarter that ended in Mar. 2024 was $-76.4 Mil. Axonics's average total tangible assets for the quarter that ended in Mar. 2024 was $538.9 Mil. Therefore, Axonics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -14.19%.

The historical rank and industry rank for Axonics's Return-on-Tangible-Asset or its related term are showing as below:

AXNX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -170.6   Med: -28.03   Max: -1.2
Current: -3.18

During the past 8 years, Axonics's highest Return-on-Tangible-Asset was -1.20%. The lowest was -170.60%. And the median was -28.03%.

AXNX's Return-on-Tangible-Asset is ranked worse than
50.69% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: -2.745 vs AXNX: -3.18

Axonics Return-on-Tangible-Asset Historical Data

The historical data trend for Axonics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Return-on-Tangible-Asset Chart

Axonics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -40.89 -19.56 -23.62 -14.66 -1.20

Axonics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.69 -6.20 3.31 5.13 -14.19

Competitive Comparison of Axonics's Return-on-Tangible-Asset

For the Medical Devices subindustry, Axonics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axonics's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axonics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Axonics's Return-on-Tangible-Asset falls into.



Axonics Return-on-Tangible-Asset Calculation

Axonics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-6.088/( (478.686+539.131)/ 2 )
=-6.088/508.9085
=-1.20 %

Axonics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-76.448/( (539.131+538.596)/ 2 )
=-76.448/538.8635
=-14.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Axonics  (NAS:AXNX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Axonics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Axonics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Axonics (Axonics) Business Description

Traded in Other Exchanges
Address
26 Technology Drive, Irvine, CA, USA, 92618
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.
Executives
Karen Noblett officer: Chief Medical Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese officer: Chief Financial Officer 15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen officer: See Remarks 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr officer: Chief Commercial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama officer: Chief Operating Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock officer: Chief Marketing Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen director, officer: Chief Executive Officer
Esteban Lopez director 6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara director C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms director, 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera 10 percent owner 374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski director, 10 percent owner 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920